Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006012 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 1 study of Lung Cancer and Radiation Toxicity, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 20
- Study locations
NCT00006012: Completed Phase 1 study of Lung Cancer and Radiation Toxicity, sponsored by Alliance for Clinical Trials in Oncology.
NCT00006012 is a Phase 1 study of Lung Cancer and Radiation Toxicity that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 73 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006012, a Phase 1 study of Lung Cancer and Radiation Toxicity, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy before, during, and after radiation therapy in treating patients who have limited-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG amifostine trihydrate
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
- Galesburg Clinic - Galesburg
- Galesburg Cottage Hospital - Galesburg
- InterCommunity Cancer Center of Western Illinois - Galesburg
- Mason District Hospital - Havana
- Hopedale Medical Complex - Hopedale
- Joliet Oncology Hematology Associates, Limited - West - Joliet
- Kewanee Hospital - Kewanee
- McDonough District Hospital - Macomb
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
- Community Hospital of Ottawa - Ottawa
- Oncology Hematology Associates of Central Illinois - Ottawa - Ottawa
- Cancer Treatment Center at Pekin Hospital - Pekin
Arizona
- CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2001-02 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
What the finished NCT00006012 record still lists
NCT00006012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00006012 names 20 study sites across 3 states, led by Illinois, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00006012 about?
NCT00006012 is a clinical study titled "Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more cancer cells. PURPOSE: Phase II trial to study the...
What is the current status of trial NCT00006012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2001-02. Estimated completion is 2006-05.
What conditions does trial NCT00006012 study?
This clinical trial studies the following conditions: Lung Cancer, Radiation Toxicity, Drug/Agent Toxicity by Tissue/Organ.
What interventions are being tested in trial NCT00006012?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00006012?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006012 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006012's enrollment target sits among peer trials
73 221st of 409 higher than 189 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia